Retatrutide
GLP-3 (RT)
Synthetic peptide studied as a triple GIP, GLP-1 and glucagon receptor agonist
1 × $40 = $40. Applied in your cart.
- Every batch tested by an independent laboratory — identity by HPLC and mass spec.
- Dispatched on business days once payment has cleared. Free shipping over $100 — flat $10 otherwise.
- Discreet packaging, tracked and insured on every shipment.
For laboratory and research use only · Not for human consumption
- Certificate
- 99.80% purity
- Class
- Triple receptor agonist
- Sizes
- 10mg · 20mg · 30mg · 40mg · 60mg
- Molecular weight
- 4731.0 g/mol
- Form
- Lyophilised powder, sealed glass vial
- Storage
- Cool, dry and dark; refrigerate once reconstituted
Measured, not claimed.
Purity by HPLC
From this lot's own certificate, published exactly as the laboratory issued it.
- Lot
- GLP3R60-1001
- Tested
- Aug 10, 2026
- Laboratory
- AMINO METRICS
3 earlier lots are in the archive.
Analysed against
- Identity
- HPLC + mass spec
- Purity
- HPLC · figure on the batch COA
- Net peptide content
- HPLC
- Heavy metals
- ICP-MS
- Sterility
- PCR
- Endotoxin
- USP <85>
What it is
GLP-3 (RT) is a synthetic peptide agonist designed to engage three related class B G-protein-coupled receptors at once: the GIP receptor, the GLP-1 receptor and the glucagon receptor. Adding glucagon receptor activity to a dual incretin scaffold is the structural question the molecule exists to answer, which is why it recurs as a reference point in comparative receptor pharmacology.
It ships as a lyophilised powder in a sealed glass vial across 10 mg, 20 mg, 30 mg, 40 mg and 60 mg presentations. Every lot is accompanied by a Certificate of Analysis documenting identity and purity. Sold as a laboratory reference material for research use only, and not for human or veterinary use.
What the research explores
Triple receptor agonism is a comparatively recent structural strategy, and the literature around it remains largely preclinical and mechanistic. Areas under study include:
- Agonist potency and selectivity ratios across GIPR, GLP-1R and the glucagon receptor
- Whether balanced or deliberately skewed receptor activity produces different signalling signatures in vitro
- cAMP response profiles and desensitisation behaviour in transfected cell lines
- Hepatic and adipose tissue signalling readouts in rodent models
- Pharmacokinetic consequences of fatty-acid acylation and albumin binding
These bullets summarise published research directions. They are not statements of outcome, benefit or effect. Elements DNA supplies this compound for in vitro and preclinical laboratory work only and makes no human-use representation of any kind.
Questions
How should the vial be stored?
Keep the sealed vial cool, dry and out of direct light until opened. Once reconstituted, keep it refrigerated and treat the solution as short-lived. Avoid repeated freeze-thaw cycles, which degrade peptide integrity.
How is the lyophilised powder reconstituted?
Solvent is typically introduced slowly down the inner wall of the vial and dissolved by swirling rather than shaking. The researcher determines solvent, concentration and protocol. We do not supply dosing or administration guidance of any kind.
What does the Certificate of Analysis cover?
The batch COA documents identity and chromatographic purity for your specific lot, with the lot identifier and test date. It describes the material as characterised in the laboratory and is not a clinical or regulatory approval.
What arrives in the shipment?
One sealed glass vial of lyophilised powder in the presentation selected, protectively packaged and batch-labelled. Reconstitution solvent and laboratory consumables are not included.
Which lot is Retatrutide's published certificate for?
Lot GLP3R60-1001, measured 99.80% by HPLC, tested Aug 10, 2026, by AMINO METRICS. The full certificate, including the laboratory's own assay rows, is published at /coa/31A3-C088-77CF-BF26-3E65-B12B-632E-9FCD-F394-9044-44F1-908D.
Literature
2 publications · 2024
Peer-reviewed publications indexed on PubMed that discuss Retatrutide. Listed for reference only — inclusion is not a claim about this product or its effects.
- 2024Retatrutide
Ramsbacher N · Clinical diabetes : a publication of the American Diabetes Association
PMID 39429457 · doi 10.2337/cd24-0062
- 2024Gut hormones and appetite regulation
Hong SH, Choi KM · Current opinion in endocrinology, diabetes, and obesity
PMID 38511400 · doi 10.1097/MED.0000000000000859
Products are supplied strictly for laboratory and research use. They are not for human or veterinary consumption, and have not been evaluated by the U.S. Food and Drug Administration for the diagnosis, treatment, cure, or prevention of any condition.